FDA 510(k) FDA class 2 Substantially Equivalent 🇺🇸 United States

VIDAS NT-PROBNP ASSAY, MODEL: 30 449

K Number: K073091 · Decision Feb 29, 2008
Classifications
1
FEI Numbers
37
Registration Numbers
37
Same Product Code
44
Applicant Total
251
Review Days
120

Research this 510(k) in seconds

The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.

Free to try · every answer cites its records

Basic Information

Device Name
VIDAS NT-PROBNP ASSAY, MODEL: 30 449
K Number
K073091
Device Class
FDA class 2
Clearance Type
Traditional
Regulation Number
862.1117
Medical Specialty
Clinical Chemistry
Decision
Substantially Equivalent
Statement or Summary
Summary
Applicant
bioMerieux, Inc.
Date Received
November 1, 2007
Decision Date
February 29, 2008
Product Code
NBC
Advisory Committee
Clinical Chemistry
Review Advisory Committee
CH
Third Party
N

Classifications

This FDA 510(k) entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NBC Test, Natriuretic Peptide

Similar 510(k) Clearances

Other 510(k) clearances with the same product code (NBC), ordered by most recent decision date.

View all

Other Clearances by bioMerieux, Inc.

K Number Device Name
K260282 VITEK 2 AST-Streptococcus Inducible Clindamycin Resistance
K251579 VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K234012 VITEK COMPACT PRO
K232967 VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)
K232963 VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)
K240279 VIDAS TBI (GFAP, UCH-L1)
K234000 VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL)
K232201 VITEK 2 AST-Streptococcus Penicillin (<=0.06 - =>8 µg/mL), VITEK 2 Streptococcus Penicillin (<=0.06 - >=8 µg/mL), VITEK 2 Streptococcus Penicillin
K230864 VITEK 2 AST-Gram Positive Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP Daptomycin
K222378 VITEK 2 AST-Gram Negative Levofloxacin (</=0.125 ->/=8 ug/mL)
Search all 251 clearances from bioMerieux, Inc. →